Krystal Biotech

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Krystal Biotech sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 8 currently recruiting 3 completed early-phase tilt top decile by trial count

Krystal Biotech: 13 sponsored US clinical trials, 8 recruiting.

Krystal Biotech sponsors 13 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dystrophic Epidermolysis Bullosa, with 3 trials.

Top-decile sponsor footprint

Krystal Biotech ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 1

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

NCT06999733
RECRUITING Phase 3

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750
RECRUITING

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

NCT06563414
RECRUITING Phase 1

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

NCT06228326
RECRUITING Phase 1

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

NCT06049082
RECRUITING Phase 1

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT05970497
RECRUITING Phase 1

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

NCT05504837
RECRUITING

Long-Term Follow-up Protocol

NCT04917887
ACTIVE NOT RECRUITING Phase 1

A Study Assessing KB304 for the Treatment of Wrinkles in Women

NCT06724900
ACTIVE NOT RECRUITING Phase 1

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900
COMPLETED Phase 3

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

NCT04917874
COMPLETED Phase 3

Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

NCT04491604
COMPLETED Phase 1

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

NCT03536143

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 3 3

Therapeutic Areas

Dystrophic Epidermolysis Bullosa 3
Dominant Dystrophic Epidermolysis Bullosa 2
Recessive Dystrophic Epidermolysis Bullosa 2
Wrinkles in Decolletage 1
Décolleté Wrinkles 1
Skin Thickness 1
Skin Roughness 1
Epidermolysis Bullosa Dystrophica Dominans 1
Epidermolysis Bullosa Dystrophica, Recessive 1
Fine Lines 1

What is open in the Krystal Biotech pipeline

8 recruiting of 13 indexed (62% open); 3 completed (23%).

Phase mix: 3 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Dystrophic Epidermolysis Bullosa (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Krystal Biotech: open-pipeline peers nationwide

Peers matched on 13 registered trials and 62% open enrollment, not the therapeutic-area sidebar.

Krystal Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Krystal BiotechAdaptimmuneAgennixAkili Interactive LabsAlumisTempus AICanadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care System
Krystal Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Krystal Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 62% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Krystal Biotech page

13 registered trials is a research-attention snapshot, not an endorsement of Krystal Biotech or any single study.

  • 8 of Krystal Biotech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Dystrophic Epidermolysis Bullosa is the condition Krystal Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dystrophic Epidermolysis Bullosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Krystal Biotech pipeline card: 13 registered trials from official public datasets.Report a data error.